{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T15:47:04Z","timestamp":1782748024008,"version":"3.54.5"},"reference-count":46,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T00:00:00Z","timestamp":1779321600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Public Health"],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>The SYMPATICO trial demonstrated that ibrutinib combined with venetoclax significantly improved progression-free survival in patients with relapsed or refractory (R\/R) mantle cell lymphoma (MCL). This study evaluated the cost-effectiveness of the combination of ibrutinib\u2013venetoclax for R\/R MCL from the healthcare perspectives of China and the United States (US).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A partitioned survival model with a 35-year simulation time horizon was developed to compare the cost-effectiveness of ibrutinib\u2013venetoclax versus ibrutinib\u2013placebo. Primary outcomes included total costs, life-years (LYs), quality-adjusted life-years (QALYs), and incremental cost-effectiveness ratios (ICERs). The robustness of the model was evaluated through one-way sensitivity analysis (OWSA) and probabilistic sensitivity analysis (PSA).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Base-case analysis showed that the ICER of ibrutinib\u2013venetoclax versus ibrutinib\u2013placebo was $128,183.93\/QALY in China, which was significantly higher than the willingness-to-pay (WTP) threshold of $40,334\/QALY. It was still not cost-effective below the $150,000\/QALY WTP threshold in the US, with an ICER of $951,082.87\/QALY. OWSA demonstrated the robustness of the model. PSA showed that ibrutinib\u2013venetoclax had a 0% probability of being cost-effective under the current WTP thresholds in China and the US. Price reduction analysis indicated that in China, reducing the price of venetoclax to 20% of its original cost could achieve cost-effectiveness with a 60.80% probability. In the US, a combined price reduction of ibrutinib and venetoclax to 22.53% of their original costs is necessary to achieve a 50% probability of cost-effectiveness.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Ibrutinib-venetoclax is unlikely to be cost-effective versus ibrutinib\u2013placebo for R\/R MCL in both China and the US.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fpubh.2026.1817037","type":"journal-article","created":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T05:43:38Z","timestamp":1779342218000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Cost-effectiveness analysis of ibrutinib plus venetoclax for relapsed or refractory mantle cell lymphoma in China and the United States"],"prefix":"10.3389","volume":"14","author":[{"given":"Jing","family":"He","sequence":"first","affiliation":[{"name":"School of Medicine, University of Electronic Science and Technology of China","place":["Chengdu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xianxi","family":"Liu","sequence":"additional","affiliation":[{"name":"School of Nursing, Chengdu Medical College","place":["Chengdu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qing","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Nursing, Sichuan Clinical Research Center for Cancer, Sichuan Cancer Hospital & Institute, Sichuan Cancer Center, University of Electronic Science and Technology of China","place":["Chengdu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,5,21]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"229","DOI":"10.3322\/caac.21834","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J Clin"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"48692","DOI":"10.18632\/oncotarget.8961","article-title":"Mantle cell lymphoma in the era of precision medicine-diagnosis, biomarkers and therapeutic agents","volume":"7","author":"Inamdar","year":"2016","journal-title":"Oncotarget"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"2021","DOI":"10.3390\/curroncol29030164","article-title":"Cost-effectiveness of brexucabtagene autoleucel versus best supportive care for the treatment of relapsed\/refractory mantle cell lymphoma following treatment with a Bruton\u2019s tyrosine kinase inhibitor in Canada","volume":"29","author":"Ball","year":"2022","journal-title":"Curr Oncol"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"1559","DOI":"10.1182\/blood-2015-10-673145","article-title":"Postibrutinib outcomes in patients with mantle cell lymphoma","volume":"127","author":"Martin","year":"2016","journal-title":"Blood"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"684","DOI":"10.1111\/bjh.16416","article-title":"Efficacy of R-BAC in relapsed, refractory mantle cell lymphoma post BTK inhibitor therapy","volume":"189","author":"McCulloch","year":"2020","journal-title":"Br J Haematol"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"660","DOI":"10.13286\/j.1001-5213.2025.06.09","article-title":"Pharmacoeconomics of relapsed or refractory mantle cell lymphoma: a systematic review","volume":"45","author":"Tan","year":"2025","journal-title":"Chin J Hosp Pharm"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"20","DOI":"10.3390\/ijms20184417","article-title":"Advances in molecular biology and targeted therapy of mantle cell lymphoma","volume":"20","author":"Klener","year":"2019","journal-title":"Int J Mol Sci"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"63","DOI":"10.19546\/j.issn.1674-3830.2019.1.016","article-title":"Average annual economic burden of recurrent mantle cell lymphoma (MCL) in China","author":"Zhu","year":"2019","journal-title":"China Health Insur"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"927","DOI":"10.21873\/anticanres.14846","article-title":"Adverse events and economic burden among patients receiving systemic treatment for mantle cell lymphoma: a real-world retrospective cohort study","volume":"41","author":"Kabadi","year":"2021","journal-title":"Anticancer Res"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1016\/S1470-2045(24)00682-X","article-title":"Ibrutinib plus venetoclax in relapsed or refractory mantle cell lymphoma (SYMPATICO): a multicentre, randomised, double-blind, placebo-controlled, phase 3 study","volume":"26","author":"Wang","year":"2025","journal-title":"Lancet Oncol"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"2895","DOI":"10.1007\/s10238-023-01007-2","article-title":"Expert consensus on the management of chronic lymphocytic leukaemia in Asia","volume":"23","author":"Tse","year":"2023","journal-title":"Clin Exp Med"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.jval.2021.11.1351","article-title":"Consolidated health economic evaluation reporting standards 2022 (CHEERS 2022) statement: updated reporting guidance for health economic evaluations","volume":"25","author":"Husereau","year":"2022","journal-title":"Value Health"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"1118","DOI":"10.6004\/jnccn.2023.0057","article-title":"NCCN guidelines\u00ae insights: B-cell lymphomas, version 6.2023","volume":"21","author":"Zelenetz","year":"2023","journal-title":"J Natl Comprehens Cancer Netw"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"2","DOI":"10.13455\/j.cnki.cjcor.113494-20230118-0032","article-title":"Clinical practice guideline for lymphoma in China (2023 version)","volume":"30","author":"Yuankai","year":"2023","journal-title":"Chin J Clin Oncol Rehabil"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"2468070","DOI":"10.1080\/21645515.2025.2468070","article-title":"Cost-effectiveness of trastuzumab deruxtecan as a second-line treatment for HER2-mutant advanced non-small cell lung cancer","volume":"21","author":"Cai","year":"2025","journal-title":"Hum Vaccin Immunother"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"1442","DOI":"10.1080\/10428194.2023.2215888","article-title":"Cost-effectiveness of brexucabtagene autoleucel for relapsed\/refractory mantle cell lymphoma","volume":"64","author":"Marchetti","year":"2023","journal-title":"Leuk Lymphoma"},{"key":"ref17","volume-title":"China guidelines for pharmacoeconomic, evaluations. China guidelines for pharmacoeconomic evaluations","author":"Liu","year":"2020"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"796","DOI":"10.1056\/NEJMp1405158","article-title":"Updating cost-effectiveness--the curious resilience of the $50,000-per-QALY threshold","volume":"371","author":"Neumann","year":"2014","journal-title":"N Engl J Med"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.1001\/jama.2016.12195","article-title":"Recommendations for conduct, methodological practices, and reporting of cost-effectiveness analyses: second panel on cost-effectiveness in health and medicine","volume":"316","author":"Sanders","year":"2016","journal-title":"JAMA"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1186\/1471-2288-12-9","article-title":"Enhanced secondary analysis of survival data: reconstructing the data from published Kaplan-Meier survival curves","volume":"12","author":"Guyot","year":"2012","journal-title":"BMC Med Res Methodol"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"1525","DOI":"10.1007\/s40273-019-00830-4","article-title":"A comparison of different analysis methods for reconstructed survival data to inform cost-effectiveness analysis","volume":"37","author":"Djalalov","year":"2019","journal-title":"PharmacoEconomics"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1007\/s40273-013-0064-3","article-title":"Overview of parametric survival analysis for health-economic applications","volume":"31","author":"Ishak","year":"2013","journal-title":"PharmacoEconomics"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1177\/0272989X12472398","article-title":"Survival analysis for economic evaluations alongside clinical trials--extrapolation with patient-level data: inconsistencies, limitations, and a practical guide","volume":"33","author":"Latimer","year":"2013","journal-title":"Med Decis Mak"},{"key":"ref24","volume-title":"Red Book: DrugPoint Summary","year":"2025"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"390","DOI":"10.18553\/jmcp.2022.28.4.390","article-title":"Cost-effectiveness and value of information analyses of Bruton's tyrosine kinase inhibitors in the treatment of relapsed or refractory mantle cell lymphoma in the United States","volume":"28","author":"Alrawashdh","year":"2022","journal-title":"J Manag Care Spec Pharm"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"e250033","DOI":"10.1001\/jamanetworkopen.2025.0033","article-title":"Cost-effectiveness of pembrolizumab with chemoradiotherapy for locally advanced cervical cancer","volume":"8","author":"Courtney","year":"2025","journal-title":"JAMA Netw Open"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"e068943","DOI":"10.1136\/bmjopen-2022-068943","article-title":"Prophylaxis for Pneumocystis carinii pneumonia in non-Hodgkin's lymphoma undergoing R-CHOP21 in China: a meta-analysis and cost-effectiveness analysis","volume":"13","author":"Huang","year":"2023","journal-title":"BMJ Open"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"e479","DOI":"10.1016\/j.clbc.2021.01.019","article-title":"First-line treatment with ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive advanced breast cancer: a cost-effectiveness analysis","volume":"21","author":"Huang","year":"2021","journal-title":"Clin Breast Cancer"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"1309930","DOI":"10.3389\/fphar.2023.1309930","article-title":"Comparative pharmacoeconomic analysis of rituximab and traditional tacrolimus regimens in membranous nephropathy in China","volume":"14","author":"Zeng","year":"2024","journal-title":"Front Pharmacol"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"766","DOI":"10.1080\/13696998.2024.2352820","article-title":"Cost-effectiveness analysis of mosunetuzumab for treatment of relapsed or refractory follicular lymphoma after two or more lines of systemic therapy in the United States","volume":"27","author":"Matasar","year":"2024","journal-title":"J Med Econ"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"29","DOI":"10.19450\/j.cnki.jcrh.2022.05.006","article-title":"Cost-utility analysis of Zanubrutinib in the treatment of relapsed and refractory adult mantle cell lymphoma","volume":"9","author":"Shi","year":"2022","journal-title":"Chin Res Hosp"},{"key":"ref32","doi-asserted-by":"publisher","first-page":"730","DOI":"10.1080\/13696998.2022.2079317","article-title":"Cost-effectiveness analysis of KTE-X19 CAR T therapy versus real-world standard of care in patients with relapsed\/refractory mantle cell lymphoma post BTKi in England","volume":"25","author":"Petersohn","year":"2022","journal-title":"J Med Econ"},{"key":"ref33","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1136\/jitc-2020-000648","article-title":"Current challenges for assessing the long-term clinical benefit of cancer immunotherapy: a multi-stakeholder perspective","volume":"8","author":"Quinn","year":"2020","journal-title":"J Immunother Cancer"},{"key":"ref34","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1080\/13696998.2021.1894158","article-title":"Cost-effectiveness for KTE-X19 CAR T therapy for adult patients with relapsed\/refractory mantle cell lymphoma in the United States","volume":"24","author":"Simons","year":"2021","journal-title":"J Med Econ"},{"key":"ref35","doi-asserted-by":"publisher","first-page":"101157","DOI":"10.1016\/j.lanwpc.2024.101157","article-title":"Impact of competition on reimbursement decisions for cancer drugs in China: an observational study","volume":"50","author":"Guan","year":"2024","journal-title":"Lancet Reg Health Western Pacific"},{"key":"ref36","doi-asserted-by":"publisher","first-page":"804237","DOI":"10.3389\/fphar.2021.804237","article-title":"Impact of the pilot volume-based drug purchasing policy in China: interrupted time-series analysis with controls","volume":"12","author":"Chen","year":"2021","journal-title":"Front Pharmacol"},{"key":"ref37","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1186\/2052-3211-7-9","article-title":"Healthcare reform in the United States and China: pharmaceutical market implications","volume":"7","author":"Daemmrich","year":"2014","journal-title":"J Pharm Policy Pract"},{"key":"ref38","volume-title":"Medicare Drug Price Negotiation Program: Selected Drugs for Initial Price Applicability Year 2026 and Response to Comments","year":"2024"},{"key":"ref39","doi-asserted-by":"publisher","first-page":"2542","DOI":"10.1016\/j.arthro.2025.01.031","article-title":"Editorial commentary: the crisis of government-sponsored health care in America","volume":"41","author":"Neviaser","year":"2025","journal-title":"Arthroscopy"},{"key":"ref40","volume-title":"Selected Drugs and Negotiated Prices","year":"2024"},{"key":"ref41","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1200\/JCO.2012.42.7906","article-title":"Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed\/refractory B-cell malignancies","volume":"31","author":"Advani","year":"2013","journal-title":"J Clin Oncol"},{"key":"ref42","doi-asserted-by":"publisher","first-page":"1414","DOI":"10.19746\/j.cnki.issn1009-2137.2024.05.017","article-title":"Clinical study of Ibrutinib combined with Venetoclax regimen in the treatment of relapsed\/refractory diffuse large B-cell lymphoma","volume":"32","author":"Yang Man","year":"2024","journal-title":"J Exp Hematol"},{"key":"ref43","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1016\/j.jval.2022.07.009","article-title":"A guide to selecting flexible survival models to inform economic evaluations of cancer immunotherapies","volume":"26","author":"Palmer","year":"2023","journal-title":"Value Health"},{"key":"ref44","doi-asserted-by":"publisher","first-page":"3750","DOI":"10.1007\/s00259-023-06332-y","article-title":"Is PSMA PET\/CT cost-effective for the primary staging in prostate cancer? First results for European countries and the USA based on the proPSMA trial","volume":"50","author":"Holzgreve","year":"2023","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"ref45","doi-asserted-by":"publisher","first-page":"e086251","DOI":"10.1136\/bmjopen-2024-086251","article-title":"Is First-Line Treatment with Polatuzumab Vedotin-Rituximab-Cyclophosphamide, Doxorubicin and Prednisone (Pola-R-Chp) for Previously Untreated Diffuse Large B-Cell Lymphoma Cost-Effective in China? A Cost-Effectiveness Analysis Using a Markov Model","volume":"15","author":"Dong","year":"2025","journal-title":"BMJ Open"},{"key":"ref46","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1016\/j.jval.2019.02.001","article-title":"Cost-Effectiveness of Cryoballoon Ablation Versus Radiofrequency Ablation for Paroxysmal Atrial Fibrillation in China: Results Based on Real-World Data","volume":"22","author":"Ming","year":"2019","journal-title":"Value in Health"}],"updated-by":[{"DOI":"10.3389\/fpubh.2026.1894932","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T00:00:00Z","timestamp":1782691200000}}],"container-title":["Frontiers in Public Health"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpubh.2026.1817037\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T15:23:56Z","timestamp":1782746636000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpubh.2026.1817037\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,21]]},"references-count":46,"alternative-id":["10.3389\/fpubh.2026.1817037"],"URL":"https:\/\/doi.org\/10.3389\/fpubh.2026.1817037","relation":{},"ISSN":["2296-2565"],"issn-type":[{"value":"2296-2565","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,21]]},"article-number":"1817037"}}